Abstract
Carbocyclic nucleoside analogues are an essential class of antiviral agents and are commonly used in the treatment of viral diseases (hepatitis B, AIDS). Recently, we reported the racemic synthesis and the anti-human immunodeficiency virus activities (HIV) of 3′-fluoro-5′-norcarbocyclic nucleoside phosphonates bearing purines as heterocyclic base. Based on these results, the corresponding racemic norcarbocyclic nucleoside phosphonates bearing pyrimidine bases were synthesized. The prepared compounds were evaluated against HIV, but none of them showed marked antiviral activity compared to their purine counterparts.
Highlights
Nucleoside analogues have been an important part of the therapeutic arsenal used in the treatment of viral diseases for several years [1]
As illustrated with the approval of carbocyclic nucleosides such as abacavir and entecavir as anti-human immunodeficiency virus activities (HIV) and anti-HBV drugs, respectively, the design and synthesis of novel carbocyclic scaffolds could lead to the discovery of new antiviral agents [2,3]
50 -norcarbocyclic nucleoside phosphonates [4,5] as potential anti-viral agents, we have described the synthesis and the anti-HIV activities of 30 -fluoro-50 -norcarbocyclic nucleoside phosphonates bearing purines as heterocyclic base (Figure 1) [6]
Summary
Nucleoside analogues have been an important part of the therapeutic arsenal used in the treatment of viral diseases for several years [1]. 50 -norcarbocyclic nucleoside phosphonates [4,5] as potential anti-viral agents, we have described the synthesis and the anti-HIV activities of 30 -fluoro-50 -norcarbocyclic nucleoside phosphonates bearing purines as heterocyclic base (Figure 1) [6]. In such structures, the presence of a P-C bond instead of the hydrolysable P-O induces a metabolic stability of the linkage mimicking the phosphate moiety. Exampleof ofantiviral antiviralcarbocyclic carbocyclicnucleosides nucleosidesand andstructures structuresof of the target compounds
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
